Ho Sup Lee
Overview
Explore the profile of Ho Sup Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Oh S, Lee T, Lee S, Kim N, Pak M, et al.
Br J Haematol
. 2025 Mar;
PMID: 40065083
No abstract available.
2.
Jung S, Koh Y, Kim M, Kim J, Moon J, Min C, et al.
Blood Res
. 2025 Feb;
60(1):9.
PMID: 39903326
Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this...
3.
Lee J, Choi J, Min C, Park S, Jo J, Lee Y, et al.
Haematologica
. 2024 Jun;
109(11):3681-3692.
PMID: 38841794
Carfilzomib, lenalidomide, and dexamethasone (KRd) combination therapy improves the survival of patients with relapsed and/or refractory multiple myeloma (RRMM). Nonetheless, evidence on the use of KRd in Asian populations remains...
4.
Baek D, Song G, Lee H, Do Y, Lee J, Yhim H, et al.
Front Oncol
. 2024 May;
14:1380492.
PMID: 38715775
Background: Elderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) undergoing reduced intensity R-CHOP therapy are at a heightened risk of acquiring infections, notably coronavirus disease 2019 (COVID-19) infection. This...
5.
Park C, Lee H, Kang K, Lee W, Do Y, Kwak J, et al.
Nat Commun
. 2024 Mar;
15(1):2776.
PMID: 38555311
Potential synergism between Bruton's tyrosine kinase (BTK) inhibitor and lenalidomide in treating aggressive B-cell lymphoma has been suggested. Here, the authors report a single-arm phase II clinical trial of combination...
6.
Yu J, Jung S, Choi J, Jun S, Lee H, Kim D
Cancer Diagn Progn
. 2024 Mar;
4(2):172-181.
PMID: 38434923
Background/aim: Interim positron emission tomography/computed tomography (PET/CT) scan is a valuable tool for assessing the early metabolic response to chemotherapy in diffuse large B-cell lymphoma (DLBCL). Although radiotherapy is an...
7.
Cho H, Kim K, Yoon S, Jung S, Lee J, Moon J, et al.
Hemasphere
. 2024 Mar;
8(1):e33.
PMID: 38434530
No abstract available.
8.
Baek D, Moon J, Lee J, Kang K, Lee H, Eom H, et al.
Blood Cancer J
. 2023 Jun;
13(1):95.
PMID: 37365207
This study aimed to identify the benefits of autologous-stem cell transplantation (auto-SCT) and allogeneic-SCT (allo-SCT) in patients with aggressive T-cell lymphomas to aid in the selection of transplantation type in...
9.
Baek D, Park H, Sohn S, Kim D, Kim I, Ahn J, et al.
Korean J Intern Med
. 2023 Jun;
38(5):734-746.
PMID: 37334511
Background/aims: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL). Methods: Patients with newly diagnosed ALL, aged ≥...
10.
Kim D, Jeong S, Kong S, Lee S, Lim S, Oh S, et al.
Sci Rep
. 2023 Feb;
13(1):2551.
PMID: 36781859
Several guidelines classify autologous stem cell transplantation (ASCT) as a low to intermediate risk group for infection. In a nationwide population-based study, using the Korean Health Insurance Review and Assessment...